Therefore, the inhibitory effect of rosiglitazone on MMP-9 found in the present study may contribute to beneficial effects of rosiglitazone on cardiovascular risk of the patients with previous acute myocardial infarction. The gene discussed is MMP9; the disease is myocardial infarction.